文献速递神经免疫神经肌肉病

微管相关蛋白1B:新型副肿瘤生物标志物

Microtubule-associated protein 1B: Novel paraneoplastic biomarker.
PubMed 文献 · Ann Neurol · 2017-01-01

该研究确认微管相关蛋白1B(MAP1B)是先前所述浦肯野细胞胞质抗体2型(PCA-2)的抗原,并分析其频率及临床、肿瘤和血清学关联。96例PCA-2-IgG阳性患者中95例IgG结合重组MAP1B,79%可评估患者检出肿瘤(多为小细胞肺癌),2015年检测率0.024%。

要点

  • MAP1B是PCA-2抗体的抗原,对副肿瘤神经综合征具有高预测价值。
  • PCA-2阳性患者中79%检出肿瘤,多数为小细胞肺癌。
  • PCA-2检测率(0.024%)与amphiphysin IgG相当,高于ANNA-2和PCA-Tr。

核心结论

  • MAP1B是副肿瘤神经疾病的新型靶抗原,对小细胞肺癌具有高预测价值。

研究设计与样本

  • 回顾性分析1993-2016年连续118例PCA-2-IgG阳性患者中96例的存档血清或脑脊液。

主要发现

  • 96例患者中95例血清或脑脊液IgG结合重组MAP1B,98例健康或疾病对照均不结合。
  • 17.5%患者IgG同时结合MAP1A。
  • PCA-2常伴小细胞癌其他神经自身抗体:CRMP5 IgG占26%,ANNA-1(抗Hu)IgG占13%。
  • 95例患者神经表现:周围神经病53%,小脑性共济失调/辨距不良/构音障碍38%,脑病27%。
  • 84例可评估患者中66例(79%)检出肿瘤,多数为小细胞肺癌。

关键数值与推荐

  • 2015年约70,000例接受神经自身抗体检测的患者中,MAP1B(PCA-2)自身抗体检测率为0.024%。
  • amphiphysin IgG检测率为0.026%,ANNA-2(抗Ri)为0.016%,PCA-Tr(DNER)为0.006%。

临床怎么用

  • MAP1B(PCA-2)应纳入综合性副肿瘤神经自身抗体评估。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To report the identification of microtubule-associated protein (MAP) 1B as the antigen of the previously described Purkinje cell cytoplasmic antibody type 2 (PCA-2) antibody, its frequency, and clinical, oncological, and serological associations. METHODS: Archival serum or cerebrospinal fluid (CSF) specimens were available from 96 of 118 consecutive PCA-2-IgG-seropositive patients identified during 1993-2016. The autoantigen, defined in mouse brain lysate by Western blot and mass spectrometry, was confirmed by dual immunohistochemical staining using commercial antibodies. The major antigenic region was defined by Western blot using recombinant protein fragments. RESULTS: IgG in 95 of 96 patients' serum or CSF (but in none of 98 healthy or disease control subjects' serum specimens) bound to recombinant MAP1B. A minority (17.5%) of patients' IgG also bound to MAP1A. PCA-2 was often accompanied by additional neural autoantibody markers of small-cell carcinoma, including collapsin response-mediated protein 5 (CRMP5) IgG (26%) or antineuronal nuclear antibody type 1 (ANNA-1) IgG (also known as anti-Hu; 13%). Neurological manifestations in 95 patients were (in decreasing frequency): peripheral neuropathy, 53%; cerebellar ataxia, dysmetria, or dysarthria, 38%; and encephalopathy, 27%. Cancer (majority small-cell lung carcinoma [SCLC]) was detected in 66 of 84 evaluated patients (79%). The MAP1B (PCA-2) autoantibody detection rate, among approximately 70,000 patients undergoing service neural autoantibody evaluation in 2015, was 0.024%, equaling amphiphysin IgG (0.026%) and more common than ANNA-2 (also known as anti-Ri; 0.016%) and PCA-Tr (also known as delta/notch-like epidermal growth factor-related receptor [DNER]; 0.006%). INTERPRETATION: MAP1B, the PCA-2 autoantigen, represents a novel target in paraneoplastic neurological disorders and has high predictive value for SCLC. Its relatively high prevalence, compared with other recognized paraneoplastic neural autoantibodies, justifies its testing in comprehensive paraneoplastic neural autoantibody evaluation. Ann Neurol 2017;81:266-277.

来源:Ann Neurol,查看原文。版权归原作者所有。

引用

  1. Gadoth A, Kryzer TJ, Fryer J, et al. Microtubule-associated protein 1B: Novel paraneoplastic biomarker. Ann Neurol. 2017. PMID: 28074593. doi:10.1002/ana.24872

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。